The CD27-CD70 Signaling Axis: A Key Regulator of Tumor Immunity with ANT BIO PTE. LTD.’s Research Tools

1. Concept

CD27 (TNFRSF7), a transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily, is primarily expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, thymocytes, and naive B cells. Its ligand, CD70 (a member of the tumor necrosis factor superfamily), exhibits transient and restricted expression exclusively on activated immune cells such as T cells, B cells, dendritic cells, and NK cells. Under physiological conditions, the CD27-CD70 signaling axis plays a pivotal role in regulating immune cell activation, differentiation, and adaptive immune responses—particularly promoting T cell priming, memory T cell formation, and B cell co-stimulation.

In the tumor microenvironment, this signaling axis is aberrantly regulated, contributing to tumor immune escape. Tumor cells often overexpress CD70, which chronically engages CD27 on tumor-infiltrating lymphocytes, leading to T cell exhaustion, apoptosis, and expansion of regulatory T cells. Rabbit anti-human CD27 antibodies serve as essential research tools for exploring the mechanisms of this signaling axis in tumor immunity and advancing targeted immunotherapy development.

2. Research Frontiers

Cutting-edge research on the CD27-CD70 axis has uncovered its critical role in tumor immune regulation, with significant advancements in mechanism elucidation and therapeutic development. CD70 is abnormally overexpressed in a wide range of malignancies, including non-Hodgkin's lymphoma (77%), diffuse large B-cell lymphoma (71%), renal cell carcinoma (87%), glioblastoma (42%), and pancreatic cancer (25%). This overexpression drives T cell dysfunction by inducing immune checkpoint expression (e.g., PD-1, TIM-3) and activating the CD95/CD95L apoptosis pathway, while also promoting soluble CD27 (sCD27) release to terminate anti-tumor signaling.

Preclinical studies have validated the potential of targeting this axis for immunotherapy. Agonistic CD27 antibodies have demonstrated anti-tumor efficacy in models of melanoma, lymphoma, renal cell carcinoma, and breast cancer—reducing tumor growth and enhancing tumor-specific CD8+ T cell responses. Combination therapies, such as pairing CD27 agonists with OX40/CD40 agonists or PD-1/PD-L1 inhibitors, have shown synergistic effects, improving durable immune memory and treatment outcomes.

Clinical observations further support the axis’s relevance: germline or somatic mutations/deletions in CD27/CD70 increase the risk of Hodgkin's lymphoma and diffuse large B-cell lymphoma. Ongoing research explores tumor-type-specific CD70 expression patterns, cross-talk with other immune checkpoint pathways, and the development of more selective agonists/antagonists to optimize therapeutic safety and efficacy.

3. Research Significance

Research on the CD27-CD70 signaling axis holds profound implications for tumor immunology and clinical oncology. At the fundamental level, it enhances our understanding of tumor immune escape mechanisms, revealing how aberrant ligand-receptor interactions reshape the tumor microenvironment to suppress anti-tumor immunity. This knowledge provides a framework for developing targeted strategies to restore immune competence.

Clinically, this work addresses a critical need for novel immunotherapeutic approaches, particularly for patients unresponsive to existing checkpoint inhibitors. Targeting the CD27-CD70 axis offers a new avenue to reinvigorate exhausted T cells, enhance anti-tumor immune responses, and improve treatment outcomes across multiple cancer types. Additionally, CD27 expression and sCD27 levels show promise as biomarkers for patient stratification and treatment response monitoring. Rabbit anti-human CD27 antibodies are indispensable for validating these biomarkers, elucidating signaling mechanisms, and accelerating translational research.

4. Related Mechanisms, Research Methods, and Product Applications

Related Mechanisms

The CD27-CD70 axis promotes tumor immune escape through multiple interconnected mechanisms:

• T Cell Exhaustion and Apoptosis: Chronic engagement of CD27 on T cells by tumor-derived CD70 induces expression of immune checkpoints (PD-1, TIM-3) and activates the CD95/CD95L pathway, impairing T cell function and reducing cell numbers.
• Immunosuppressive Microenvironment: CD70 overexpression promotes regulatory T cell expansion, further suppressing anti-tumor immunity.
• Soluble CD27 (sCD27) Release: CD70-induced CD27 shedding generates sCD27, which competes with membrane-bound CD27 for ligand binding, terminating downstream signaling and weakening anti-tumor responses.

Agonistic CD27 antibodies reverse these effects by activating CD27 signaling, enhancing T cell proliferation, cytokine production (e.g., interferon-γ), and memory cell formation—restoring anti-tumor immune competence.

Research Methods

Exploring the CD27-CD70 axis in tumor immunity relies on advanced immunological and molecular techniques, with rabbit anti-human CD27 antibodies as core tools:

• Flow Cytometry: Quantifies CD27 expression on immune cell subsets (T cells, NK cells) from patient samples and tumor models, enabling phenotypic analysis and cell sorting.
• Immunohistochemistry: Visualizes CD27 spatial distribution in tumor tissues and correlates expression with immune cell infiltration and clinical outcomes.
• Western Blot and Co-Immunoprecipitation: Analyzes CD27 protein levels and interactions with downstream signaling molecules (e.g., TRAF family proteins) to validate pathway activation.
• Functional Assays: Measures T cell proliferation, cytokine production (ELISA), and cytotoxicity to assess the impact of CD27 modulation on anti-tumor immune responses.
• Tumor Models: Evaluates the efficacy of CD27-targeted therapies in xenograft or syngeneic tumor models, alone or in combination with other immunotherapies.

Product Applications

ANT BIO PTE. LTD., via its sub-brand STARTER (specializing in antibodies), offers high-performance Rabbit Anti-Human CD27 Antibodies (Catalog Numbers: S0B0816, S0B8300)—rigorously validated tools for tumor immunity research. Developed using advanced antibody technology, these products exhibit exceptional specificity, affinity, and batch consistency, with validation across flow cytometry, Western Blot, and immunohistochemistry platforms. The Alexa Fluor® 488-conjugated variant (S0B8300) enables direct detection in fluorescence-based assays.

Key application scenarios include:

• Tumor Immune Microenvironment Analysis: Characterizes CD27 expression on tumor-infiltrating lymphocytes and correlates with disease progression.
• Signaling Mechanism Research: Investigates CD27 downstream pathways in T cell activation, exhaustion, and memory formation.
• Immunotherapy Development: Validates target engagement and assesses efficacy of CD27 agonists/antagonists in preclinical studies.
• Lymphoma Diagnosis: Serves as a diagnostic marker for Hodgkin's lymphoma and non-Hodgkin's lymphoma, aiding pathological classification.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering global innovative pharmaceutical companies, research institutions, and life science researchers with high-quality biological reagents and comprehensive solutions. Leveraging state-of-the-art technology platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development systems (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—we strive to accelerate scientific discovery and translational research. Our sub-brands (Absin for general reagents and kits, STARTER for antibodies, and UA for recombinant proteins) synergize to address diverse research needs, contributing to breakthroughs in tumor immunotherapy, hematology, and precision medicine. With certifications including EU 98/79/EC, ISO9001, and ISO13485, we uphold the highest standards of quality and reliability to support our mission of advancing human health through science.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.